We believe at Issels® Immuno-Oncology that integrative immunotherapy treatment plans are critical for successful patient outcomes; which is why we are so excited about the following prostate cancer risk detection and screening news:
The National Cancer Institute estimates that approximately 27,540 American men will die from prostate cancer this year. Yet, as reported in the New England Journal of Medicine, researchers have finally found their first link between inherited genes and prostate cancer — a HOXB13 gene mutation.
Researchers took samples from 5,100 prostate cancer patients who were 55 years old or younger (94 families represented) and 1,400 healthy men. After sequencing more than 200 genes, they found the following:
- 72 men in four families carried the same HOXB13 gene mutation.
- Only one man in the control group had it.
Although these results aren’t definitive proof that the mutation causes prostate cancer, it does appear to be a factor. The researchers also found two more mutations among African men, but they need a larger sampling to confirm if these mutations also play a role.
The Big Picture
Doctors trace the risk of inherited breast cancer in women through tests that look for mutations of BRCA1 and BRCA2 genes that can contribute to cancer growth. The HOXB13 mutation offers hope that doctors might one day be able to test men for genetic links in a similar fashion.
Since men with the HOXB13 gene mutation carry 10-20 times more risk of getting prostate cancer before they reach 55 years old, the discovery of this gene is a scientific breakthrough. At Issels®, we search for breakthroughs like these every single day. Contact us today for more information!